Ancilia Biosciences
anciliabio.comLocations
New York, NY, USA
industry
Biotechnology · DeepTech · Health
Size
1 - 10 employees
Stage
Other
founded in
2019
Ancilia develops novel bacterial therapies that target the viral components of the microbiome to address chronic diseases across immunology and oncology indications. Our approach harnesses the natural function of CRISPR to enhance bacterial immunity against viruses and effectively modulate the human microbiome.
Something looks off?Open jobs at Ancilia Biosciences